Valuation : BICO Group AB

Market Cap 140.73Cr 15Cr 13Cr 12Cr 11Cr 20Cr 1.4TCr 20Cr 55Cr 708.3Cr 55Cr 54Cr 2.35TCr P/E 2026 *
-6.19x
P/E 2027 * -11.1x
Enterprise Value 133.83Cr 14Cr 12Cr 11Cr 10Cr 19Cr 1.33TCr 19Cr 52Cr 673.57Cr 52Cr 51Cr 2.23TCr EV / Sales 2026 *
0.83x
EV / Sales 2027 * 0.74x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
1 day-26.24%
3 months-28.23%
6 months-1.65%
Current year-33.61%
Current year 0.35
Extreme 0.35
0.65
1 year 0.35
Extreme 0.35
0.75
3 years 0.35
Extreme 0.35
1.55
5 years 0.35
Extreme 0.35
14.8
10 years 0.35
Extreme 0.35
14.8
Manager TitleAgeSince
Chief Executive Officer 54 27/11/2023
Director of Finance/CFO 56 01/03/2026
Chief Operating Officer - 07/01/2026
Director TitleAgeSince
Director/Board Member 70 18/12/2019
Director/Board Member 37 01/03/2015
Director/Board Member - 07/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-26.24%-.--% - - 15Cr
-1.52%-1.35%+26.75%+13.86% 23TCr
+0.35%-1.24%+5.28%-17.35% 15TCr
+1.27%-1.88%-21.56%+23.29% 13TCr
+0.13%-7.27%-55.83%-13.16% 6.76TCr
+0.13%+0.33%+10.90%+18.49% 5.18TCr
+0.66%-1.69%-16.57%-13.62% 5.09TCr
-1.55%-2.30%+24.32%+29.54% 4.45TCr
-1.13%+1.34%+39.83%+47.88% 4.14TCr
+1.37%+3.35%-13.11%+47.81% 3.4TCr
Average -2.66%-0.44%+0.00%+15.19% 8.94TCr
Weighted average by Cap. -0.21%-0.56%+3.07%+9.84%

Financials

2026 *2027 *
Net sales 162.2Cr 17Cr 15Cr 14Cr 12Cr 24Cr 1.62TCr 24Cr 63Cr 816.38Cr 64Cr 62Cr 2.71TCr 168.55Cr 18Cr 15Cr 14Cr 13Cr 24Cr 1.68TCr 25Cr 66Cr 848.34Cr 66Cr 65Cr 2.81TCr
Net income -23Cr -2.37Cr -2.04Cr -1.91Cr -1.75Cr -3.29Cr -226.34Cr -3.3Cr -8.86Cr -114.25Cr -8.89Cr -8.7Cr -378.84Cr -13Cr -1.31Cr -1.13Cr -1.06Cr -96.95L -1.83Cr -125.63Cr -1.83Cr -4.92Cr -63Cr -4.94Cr -4.83Cr -210.28Cr
Net Debt -6.9Cr -71.98L -62.03L -58.16L -53.09L -1Cr -69Cr -1Cr -2.69Cr -35Cr -2.7Cr -2.64Cr -115.16Cr -17Cr -1.73Cr -1.49Cr -1.4Cr -1.28Cr -2.41Cr -165.51Cr -2.41Cr -6.48Cr -84Cr -6.5Cr -6.36Cr -277.04Cr
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
554
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
19.94SEK
Average target price
29.00SEK
Spread / Average Target
+45.44%

Quarterly revenue - Rate of surprise